CANCER DICTIONARY

ICD - 10 CODE | CANCER SITE NAME ( CSN ) | SHORT NAME ( SN )

C00 - 06 | CSN : Lip, oral cavity | SN : Lip, oral cavity

C07-08 | CSN : Salivary glands | SN : Salivary glands

C09-10 | CSN : Oropharynx | SN : Oropharynx

C11 | CSN : Nasopharynx | SN : Nasopharynx

C12-13 | CSN : Hypopharynx | SN : Hypopharynx

C15 | CSN : Oesophagus | SN : Oesophagus

C16 | CSN : Stomach | SN : Stomach

C18 | CSN : Colon | SN : Colon

C19-20 | CSN : Rectum | SN : Rectum

C21 | CSN : Anus | SN : Anus

C22 | CSN : Liver and intrahepatic bile ducts | SN : Liver

C23 | CSN : Gallbladder | SN : Gallbladder

C25 | CSN : Pancreas | SN : Pancreas

C32 | CSN : Larynx | SN : Larynx

C33-34 | CSN : Trachea, bronchus and lung | SN : Lung

C50 | CSN : Breast | SN : Breast

C52 | CSN : Vagina | SN : Vagina

C53 | CSN : Cervix uteri | SN : Cervix uteri

C54 | CSN : Corpus uteri | SN : Corpus uteri

C56 | CSN : Ovary | SN : Ovary

C60 | CSN : Penis | SN : Penis

C61 | CSN: Prostate | SN : Prostate

C62 | CSN : Testis | SN : Testis

C64 | CSN : Kidney | SN : Kidney

C67 | CSN : Bladder | SN : Bladder

C70-72 | CSN : Brain, central nervous system | SN : Brain CNS

C73 | CNS : Thyroid | SN : Thyroid

C91-95 | CNS : Leukaemia | SN : Leukaemia

The methods used to estimate the sex- and age-specific incidence rates of cancer in a specific country fall into the following broad categories, in order of priority:

METHOD CODE | DESCRIPTION

• METHOD CODE 1 : Regional (or sub-regional of the Philippines) rates projected to 2019–2024 = 17 regions
  
• METHOD CODE 2 : Most recent rates from a City registry applied to 2019 - 2024 population = 149 cities
  
• METHOD CODE 3 : Estimated from national mortality estimates by modelling, using mortality and multiplicative model of Tableau derived from 19 Hospitals cancer registry data.
  

The prevalence estimates for 2022 were computed using sex-, site-, and age-specific ratios of incidence to 1-, 3-, and 5-year prevalence from Nordic countries for the period 2006–2015.

PREVELANCE country = INCEDENCE country ( PREVELANCE nordic / INCIDENCE nordic ) * ( HDI country / HDI nordic )

These ratios were scaled using Human Development Index (HDI) ratios, with the following exceptions:

1. Cancers of the breast and prostate. For countries having high, medium and low HDI, the prevalence to incidence ratios used (Nordic countries) were from the same source for the period 1980–1989, corresponding to pre-screening activities.
2. Cancers of the oesophagus, stomach, liver, gallbladder, pancreas, and lung, and mesothelioma. Because survival is generally low for these sites, the corresponding country-specific to Nordic countries HDI ratios (HDICountry/HDINordic) were set to a minimum value (0.9 for oesophagus, liver, gallbladder, and pancreas, 0.8 for lung and mesothelioma, and 0.75 for stomach cancer).
3. Republic of Korea and Japan. Because survival from cancers of the stomach and liver differs markedly for these countries, the country-specific relative survival ratios between the Republic of Korea and Japan and the Nordic countries were used, rather than the HDI ratios.

Prevalence is available both as numbers and as proportions of the population per 100 000 persons.

The methods used to estimate the sex- and age-specific mortality rates of cancer in a specific country fall into the following broad categories, in order of priority:

METHOD CODE | DESCRIPTION |

• METHOD CODE 1 : Regional (or sub-regional of the Philippines) rates projected to 2019–2024 = 17 region

• METHOD CODE 2 : Most recent rates from a City registry applied to 2019 2019–2024 population = 149 cities

• METHOD CODE 3 : Estimated from national mortality estimates by modelling, using mortality and a multiplicative model of Tableau derived from 19 hospital cancer registry data.